These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36126024)

  • 1. Cancer risk associated with cytomegalovirus infection among solid organ transplant recipients in the United States.
    Geris JM; Spector LG; Pfeiffer RM; Limaye AP; Yu KJ; Engels EA
    Cancer; 2022 Nov; 128(22):3985-3994. PubMed ID: 36126024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease.
    Belga S; Hernandez C; Kabbani D; Cervera C
    Transpl Infect Dis; 2024 Apr; 26(2):e14227. PubMed ID: 38180285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments in the management of cytomegalovirus infection after solid organ transplantation.
    Eid AJ; Razonable RR
    Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing Proportion of High-risk Cytomegalovirus Donor-positive/Recipient-negative Serostatus in Solid Organ Transplant Recipients.
    Imlay H; Wagener MM; Vutien P; Perkins J; Singh N; Limaye AP
    Transplantation; 2023 Apr; 107(4):988-993. PubMed ID: 36173456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor Graft Cytomegalovirus Serostatus and the Risk of Arterial and Venous Thrombotic Events in Seronegative Recipients After Non-Thoracic Solid Organ Transplantation.
    Belga S; MacDonald C; Chiang D; Kabbani D; Shojai S; Abraldes JG; Cervera C
    Clin Infect Dis; 2021 Mar; 72(5):845-852. PubMed ID: 32025704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus transmission in mismatched solid organ transplant recipients: Are factors other than anti-viral prophylaxis at play?
    Hernandez C; Mabilangan C; Burton C; Doucette K; Preiksaitis J
    Am J Transplant; 2021 Dec; 21(12):3958-3970. PubMed ID: 34174153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
    San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
    Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
    Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
    Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
    Hodson EM; Ladhani M; Webster AC; Strippoli GF; Craig JC
    Cochrane Database Syst Rev; 2013 Feb; (2):CD003774. PubMed ID: 23450543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
    Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of recipient age on mortality among Cytomegalovirus (CMV)-seronegative lung transplant recipients with CMV-seropositive donors.
    Belga S; Hussain S; Avery RK; Nauroz Z; Durand CM; King EA; Massie A; Segev DL; Connor AE; Bush EL; Levy RD; Shah P; Werbel WA
    J Heart Lung Transplant; 2024 Apr; 43(4):615-625. PubMed ID: 38061469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Donor and Recipient Cytomegalovirus Serostatus on Graft and Patient Survival in Liver Transplant Recipients.
    Vutien P; Perkins J; Biggins SW; Reyes J; Imlay H; Limaye AP
    Liver Transpl; 2021 Sep; 27(9):1302-1311. PubMed ID: 33687777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
    Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
    Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact and outcomes of primary cytomegalovirus disease in seronegative abdominal solid organ transplant recipients of cytomegalovirus unexposed donors (D-/R-).
    Jorgenson MR; Descourouez JL; Yang DY; Stalter LN; Leverson GE; Parajuli S; Mandelbrot DA; Smith JA; Redfield RR
    Transpl Infect Dis; 2021 Jun; 23(3):e13564. PubMed ID: 33449413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.
    Cameron BM; Kennedy SE; Rawlinson WD; Mackie FE
    Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27704725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients.
    Imlay H; Dumitriu Carcoana AO; Fisher CE; Wong B; Rakita RM; Fishbein DP; Limaye AP
    Transpl Infect Dis; 2020 Jun; 22(3):e13255. PubMed ID: 32020736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: A systematic review of the literature.
    Anderson-Smits C; Baker ER; Hirji I
    Transpl Infect Dis; 2020 Dec; 22(6):e13396. PubMed ID: 32603496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Fisher CE; Knudsen JL; Lease ED; Jerome KR; Rakita RM; Boeckh M; Limaye AP
    Clin Infect Dis; 2017 Jul; 65(1):57-63. PubMed ID: 28369203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.